

# Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression

Johannes MHM Reul\* and Florian Holsboer

Corticotropin-releasing factor (CRF) and its related family members are implicated in stress-related disorders such as anxiety and depression. Recently, two new members of this neuropeptide family have been discovered in the brain: urocortin II (also known as stresscopin-related peptide) and urocortin III (also known as stresscopin). These urocortins are selective agonists for the CRF<sub>2</sub> receptor, show a distinct neuroanatomical localization and are involved in stress-coping responses such as anxiolysis. Thus, CRF, the urocortins and their receptors form an intricate network in the brain involved in the acute phase as well as the recovery phase of the stress response.

## Addresses

Max Planck Institute of Psychiatry, Kraepelinstrasse 2–10,  
D-80804 Munich, Germany  
\*e-mail: reul@mpipsykl.mpg.de

*Current Opinion in Pharmacology* 2002, 2:23–33

1471-4892/02/\$ – see front matter

© 2002 Elsevier Science Ltd. All rights reserved.

## Abbreviations

<b>ACTH</b>	adrenocorticotrophic hormone
<b>BNST</b>	bed nucleus of the stria terminalis
<b>CRF</b>	corticotropin-releasing factor
<b>CRFBP</b>	non-receptor CRF-binding protein
<b>CSF</b>	cerebrospinal fluid
<b>EW nucleus</b>	Edinger-Westphal nucleus
<b>GR</b>	glucocorticoid receptor
<b>HPA axis</b>	hypothalamic-pituitary-adrenocortical axis
<b>i.c.v.</b>	intracerebroventricular
<b>ILS</b>	intermediate LS
<b>LS</b>	lateral septal nucleus
<b>MR</b>	mineralocorticoid receptor
<b>PVH</b>	paraventricular hypothalamic nucleus
<b>Ucn</b>	urocortin
<b>VMH</b>	ventromedial hypothalamic nucleus

## Introduction

Anxiety and major depressive disorders are the most prominent stress-related psychiatric disorders and they impair the lives of approximately 10–15% of the population. For decades, the success of pharmacological treatment of these disorders has been dampened by various factors, including long latency of clinical effect, treatment resistance, adverse side effects, and, in the case of the anxiolytic benzodiazepines, tolerance and addictive potential. Although the themes of stress, anxiety and other stress-related disorders have been a topic of investigation continuously since the 1940s, antidepressant and anxiolytic drugs that are currently prescribed stem from the 1950s and are based on pharmacological interaction with the classic neurotransmitters.

In 1981 a new era began: corticotropin-releasing factor (CRF) was discovered as the principal mediator of the effects of stress on the hypothalamic-pituitary-adrenocortical

axis (HPA axis) and behavior [1]. Not surprisingly, clinical studies soon demonstrated that this neuropeptide is implicated in depression and anxiety disorders [2–5]. Basic research studies also presented evidence that elevated central CRF levels are involved in the etiology of stress-related physiological and behavioral disorders [6]. For the pharmacology field, the discovery of two CRF receptors and a non-receptor CRF-binding protein (CRFBP) was an immense breakthrough. With the recent discovery of more (endogenous) ligands beside CRF, the concept is dawning that CRF, its congeners and their receptors form an intricate network in the brain that potentially provides a variety of targets for drug intervention. In this review, we describe recent findings on the properties of CRF<sub>1</sub> and CRF<sub>2</sub> receptors and their ligands in the brain. Based on these exciting developments, we depict a new concept of the role of CRF<sub>1</sub> and CRF<sub>2</sub> receptors and their ligands in both the acute and recovery phase of the stress response. This concept is also presented as a framework for the pathophysiology of anxiety and major depressive disorders.

## CRF and its receptors: a growing family

The CRF family of neuropeptides has undergone considerable expansion during recent times. Until recently, together with CRF, the family comprised structurally-related peptides including urocortin (Ucn) [7], fish urotensin I [8] and amphibian sauvagine [9]. The biological actions of CRF and Ucn are mediated via two types of G-protein-coupled receptors, CRF<sub>1</sub> and CRF<sub>2</sub>, which have different expression patterns and physiological functions [10–12]. Two different splice variants of CRF<sub>2</sub> have been identified, CRF<sub>2α</sub> and CRF<sub>2β</sub>, which presented an uneven distribution between the brain (predominantly expressing CRF<sub>2α</sub>) and periphery (predominantly expressing CRF<sub>2β</sub>) in rodents [13].

Whereas CRF is relatively selective for CRF<sub>1</sub> over CRF<sub>2</sub> receptors, Ucn is bound by both CRF<sub>1</sub> and CRF<sub>2</sub> with high affinity ([10,11]; see Table 1). The question remained whether a neuropeptide existed that would selectively bind to CRF<sub>2</sub> receptors. This question was answered by the recent discovery of two selective ligands for CRF<sub>2</sub>, Ucn II (also known as stresscopin-related peptide) [14•,15•] and Ucn III (also called stresscopin) [15•,16•] (Table 1). Neither Ucn II nor Ucn III binds to CRFBP [16•], whereas CRF and Ucn do.

Thus, in mammalian brain, the CRF/Ucn receptor network comprises two receptor types and four ligands of which three (CRF, Ucn II, Ucn III) are pharmacologically monogamous and one (Ucn) is, at least regarding CRF<sub>1</sub> and CRF<sub>2</sub>, promiscuous. This network of CRF/Ucn and their receptors is further complicated by the

Table 1

## Binding properties and functional activities of members of the CRF neuropeptide family.

Peptide	Binding ( $K_i$ , nM)			cAMP generation ( $EC_{50}$ , nM)		
	hCRF <sub>1</sub>	rCRF <sub>2α</sub>	mCRF <sub>2β</sub>	hCRF <sub>1</sub>	rCRF <sub>2α</sub>	mCRF <sub>2β</sub>
CRF (rat/human)	3.3	42	47	4	20	–
CRF (sheep)	1.1	230*	320*	–	–	–
Ucn (rat)	0.32	2.2	0.62	0.15	0.063	0.087
Ucn (human)	0.4	0.3*	0.5*	–	–	–
Ucn II (human)	>100	1.7	0.50	>100	0.26	0.42
Ucn II (mouse)	>100	2.1	0.66	>100	0.14	0.05
Ucn III (human)	>100	21.7	13.5	>100	0.16	0.12
Ucn III (mouse)	>100	5.0	1.8	>100	0.073	0.081
Urotensin I (fish)	0.4	1.8*	5.7*	–	–	–
Sauvagine (frog)	0.7	0.5*	2.1*	–	–	–

Data were taken from [10,11,16\*\*,79]. Values were determined using transiently transfected COS-M6 cells (h/rCRF only), transiently or stably transfected mouse Ltk cells (h/rCRF receptors only), or stably transfected Chinese hamster ovary cells (cAMP measurements) or

their membranes (binding experiments). \*Binding experiments were conducted with  $\alpha$ - and  $\beta$ -splice variant of the human CRF<sub>2</sub> receptor. For more details, see the text for references. (–), data not available; hCRF, human CRF; mCRF, mouse CRF; rCRF, rat CRF.

presence of the CRFBP binding protein that presumably constrains the biological activity of CRF and Ucn [17].

### CRF<sub>1</sub> and CRF<sub>2</sub> in the brain: who and where are your ligands?

#### Receptor distribution

As revealed by *in situ* hybridization histochemistry studies, CRF<sub>1</sub> and CRF<sub>2</sub> mRNA show a distinct but overlapping distribution in the brain (Figure 1a; [12,18,19\*,20\*]). CRF<sub>1</sub> is widely distributed in central nervous system regions involved in sensory information processing and motor control, whereas CRF<sub>2</sub> is virtually restricted to subcortical structures (Figure 1a). Moderate levels of both receptors are expressed in the dorsal and median raphe nuclei, whereas only low levels are found in the paraventricular hypothalamic nucleus (PVH) [12,18,19\*,20\*]. Outside the brain, in the anterior pituitary, the CRF<sub>1</sub> receptor mediates the effects of CRF on adrenocorticotrophic hormone (ACTH) release and, thus, on glucocorticoid hormone secretion (Figure 1a; [10,20\*]).

#### Ligand distribution

##### Ucn

A discrepancy has been found between the localization of Ucn-immunoreactive fibers and CRF<sub>2</sub> distribution. Brain nuclei most richly endowed with Ucn mRNA (i.e. the Edinger-Westphal nucleus [EW nucleus], lateral olivary and supraoptic nuclei; Figure 1b) mainly project caudally, despite high concentrations of CRF<sub>2</sub> receptors in forebrain areas such as the bed nucleus of the stria terminalis (BNST), lateral septal nucleus (LS), and the ventromedial hypothalamic nucleus (VMH) [18]. However, an Ucn-immunoreactive projection stemming from the EW nucleus was found to terminate in the intermediate LS

(iLS) [18], but the projection ended in a region medially localized from the ventrolateral region to which CRF<sub>2</sub> is confined [19\*]. With the recent discovery of the CRF<sub>2</sub>-selective ligands Ucn II and Ucn III, answers can now be found to the question: where are the endogenous ligands for forebrain CRF<sub>2</sub>?

##### Ucn II

Ucn II mRNA shows a distinct subcortical distribution including regions known to be involved in physiological and behavioral responses to stress such as the PVH (HPA axis and autonomic control [21]), the locus coeruleus (arousal and anxiety [22]) and the arcuate nucleus (food intake and energy balance [23]), and partly overlaps with the expression of CRF (in the PVH; [24]) and Ucn (in the brainstem and spinal motor nuclei [18]) (Figure 1b). After intracerebroventricular (i.c.v.) injection of Ucn II, Fos induction was observed in the BNST, PVH, central nucleus of the amygdala, parabrachial nucleus and nucleus tractus solitarius (NTS), but was absent in other CRF<sub>2</sub>-rich locations such as the LS, raphe nuclei and VMH [14\*\*]. Given the high affinity of Ucn II for CRF<sub>2</sub>, the latter observation is unexpected and a solid explanation is still lacking. The incongruence might point to the need of additional factors required for activation of the neuron, at least in terms of Fos. Alternatively, these CRF<sub>2</sub>-expressing neurons might display activation of signal transduction pathways that do not ultimately lead to synthesis of Fos. For instance, we have shown recently that phosphorylation of CREB (cAMP response element binding protein), a transcription factor activated through CRF<sub>1</sub> and CRF<sub>2</sub>, is not necessarily correlated with Fos expression (A Bilang-Bleuel, J Rech, F Holsboer, JMHM Reul, unpublished data). Nevertheless, given the apparent resemblance

between the localizations of Ucn II and CRF, it seems pertinent that Ucn II participates in responses to stress [14\*\*]. However, their differential binding preference for CRF<sub>1</sub> and CRF<sub>2</sub> suggests that CRF and Ucn II have different functions in the stress response.

#### *Ucn III*

The localization of Ucn III in brain (Figure 1b; [15\*\*,16\*\*]) is distinct from that of CRF [24], Ucn [18] and Ucn II [14\*\*]. This most recently discovered member of the CRF neuropeptide family is found in the median pre-optic area, the rostral perifornical area (a region lateral from the PVH), the posterior part of the BNST, and the medial nucleus of the amygdala [16\*\*]. To date, unfortunately, no Fos studies have been performed with Ucn III. Of interest though is that parts of the perifornical region project to the LS (a CRF<sub>2</sub>-rich region), an area in which immunoreactivity for both Ucn and piscine urotensin I can be found [18]. Within the LS, however, Ucn and urotensin I are differentially localized: Ucn-immunoreactivity is prevalent in the medial aspect of the iLS, whereas urotensin I-immunoreactivity is concentrated in the ventrolateral aspect of this nucleus (the site where CRF<sub>2</sub> mRNA is also found; see sections on receptor and ligand distribution). It can be speculated that, given the structural relationship between urocortins and urotensin, the immunoreactivity in the ventrolateral aspect of the iLS as revealed with the piscine urotensin I antiserum might actually be Ucn III. Indeed, Ucn-III-immunoreactive fibers have recently been found in this region of the LS (and in the VMH), which align well with the sites of CRF<sub>2</sub> mRNA expression (PE Sawchenko, personal communication).

### **The role of CRF<sub>1</sub> and CRF<sub>2</sub> receptors in stress processes**

During the past few years, many studies have been conducted to discern the roles of CRF<sub>1</sub> and CRF<sub>2</sub> receptors in stress-related physiological and behavioral processes to gain insight into anxiety and major depressive disorders. Various strategies have been employed, including pharmacological approaches, mutant mice with functional deletions in the receptors and antisense oligodeoxynucleotide technology. These investigations have provided insight into the complex roles of CRF<sub>1</sub> and CRF<sub>2</sub> in the regulation of emotional behavior, HPA axis activity and autonomic function. For some processes the roles of CRF<sub>1</sub> and CRF<sub>2</sub> seem clear, whereas for others they still need to be resolved.

#### **Anxiety and emotion**

##### *CRF<sub>1</sub>*

CRF plays an important role in the regulation of anxiety-related behavior and is implicated in anxiety and depressive disorders [25–27]. Several lines of evidence point to the participation of CRF<sub>1</sub> in mediating the effects of CRF. First, CRF<sub>1</sub>, but not CRF<sub>2</sub>, binds CRF with high affinity. Second, CRF<sub>1</sub>-deficient mice show reduced anxiety-related behavior [28,29]. Third, transgenic mice overexpressing CRF show increased anxiety-related


behavior ([30]; M van Gaalen, JMHM Reul, A Gesing, MP Stenzel-Poore, F Holsboer, T Steckler, unpublished data). Fourth, central administration of CRF<sub>1</sub> antisense oligodeoxynucleotides restrain CRF-evoked and social-defeat-evoked anxiety-related behaviors and elicit anxiolytic-like effects in certain anxiety tests, whereas CRF<sub>2</sub> antisense did not exert any significant effects in these tests [31–34]. Fifth, the selective (non-peptidergic) CRF<sub>1</sub> receptor antagonists NBI27914, CRA1000, CRA1001 (anilopyrimidines), and CP154,526 (a pyrolopyrimidine) inhibit the anxiogenic action of CRF ([35,36]; for review see [37]). Anxiolytic effects have also been observed with the novel antagonists, R121919 (a phenylpyrimidine; [38]), antalarmin (a pyrolopyrimidine derivative; [39,40]), DMP904 (a pyrazolopyrimidine) and DMP696 (a pyrazolo-triazine) [41–43]. *In vivo* monitoring of the CRF<sub>1</sub> receptor in the living brain could soon become possible as a result of the recent accomplishments in the development of non-peptidergic CRF<sub>1</sub> ligands for single photon emission computed tomography (SPECT) and positron emission tomography (PET) [44,45]. This should reveal any changes in CRF<sub>1</sub> receptor expression that occur in emotional states.

##### *CRF<sub>2</sub>*

Although there is robust evidence that CRF<sub>1</sub> is highly involved in anxiety-related behavior, a role for CRF<sub>2</sub> cannot be excluded. The three lines of CRF<sub>2</sub>-deficient mice that have been described [46\*–48\*], unfortunately, do not provide a clear answer to the question about the role of this receptor in anxiety. In two lines of CRF<sub>2</sub>-deficient mice, increased anxiety-related behavior was observed [47\*,48\*], whereas in the third no changes were found [46\*]. This disparity could be caused by differences in genetic background, environmental factors and the behavioral test conditions used [49].

Recent pharmacological experiments, however, point to a much more complex involvement of the CRF<sub>2</sub> receptor in anxiety. The picture is emerging that activation of the CRF<sub>2</sub> receptor can result in anxiolysis or anxiogenesis depending on when the animal is tested and, possibly, where the receptor is localized. Radulovic and colleagues [50] observed that injection of a high (500 ng/mouse), CRF<sub>2</sub>-binding, dose of human/rat CRF into the iLS of mice increases anxiety-like behavior in the plus-maze test 30 minutes after injection, which was prevented by pretreatment with the CRF<sub>2</sub> receptor antagonist anti-sauvagine-30. Increased anxiety in the plus-maze test was also observed 30 minutes after the mice had been immobilized for 60 minutes. This post-immobilization anxiety was prevented if the animals were treated intraseptically, but not intradorsohippocampally, with anti-sauvagine-30 before the stress procedure [50]. Thus, in the short term, CRF<sub>2</sub>-mediated signaling in the iLS results in anxiogenesis. Physiologically, the CRF<sub>2</sub> receptor in this nucleus is likely to be activated by Ucn stemming from the EW nucleus [18] and, probably more so, by Ucn III from the perifornical region [16\*\*] (PE Sawchenko, personal communication). However, i.c.v. administration of the selective CRF<sub>2</sub> receptor agonists mUcn II [51\*\*] or mUcn III (EP Zorrilla, personal

Figure 1



Current Opinion in Pharmacology

communication) has no short-term effects but after four hours results in reduced anxiety-related behavior in the plus-maze test. Thus, CRF<sub>2</sub> in the brain is capable of reducing anxiety in a delayed fashion.

The anxiogenic and anxiolytic properties of CRF<sub>2</sub> are certainly not paradoxical, because they operate in different time domains after stress. Together, it can be postulated that during the acute (early) phase of the stress response

**Figure 1 legend**

Distribution of (a) CRF<sub>1</sub> and CRF<sub>2</sub> mRNA and (b) Ucn, Ucn II and Ucn III mRNA in a sagittal section of the rodent brain. The presented mRNA distribution is based on *in situ* hybridization studies reported in [12,14\*,16\*,18,19\*,20\*,80]. The drawn sagittal sections are only 2-dimensional schematic representations and, therefore, cannot be neuroanatomically exact. 7, facial nucleus; 12, hypoglossal nucleus; Amb, ambiguus nucleus; AON, anterior olfactory nucleus; AP, area postrema; Apit, anterior pituitary; ARC, arcuate nucleus; Basal G, basal ganglia; BLA, basolateral amygdala; CA1–3, fields CA1–3 of Ammon's horn, CC, corpus callosum; CeA, central nucleus of the amygdala; Cereb, cerebellum; CingCx, cingulate cortex; CoA, cortical nucleus of

the amygdala; DBB, diagonal band of Broca; Deep N, deep nuclei; DG, dentate gyrus; FrCx, frontal cortex; IC, inferior colliculi; IO, inferior olive; IPit, intermediate pituitary; LC, locus coeruleus; LDTg, laterodorsal tegmental nucleus; LSO, lateral superior olive; MA, medial nucleus of the amygdala; MePO, median preoptic area; MS, medial septum; NTS, nucleus tractus solitarius; OB, olfactory bulb; OccCx, occipital cortex; PAG, periaqueductal gray; ParCx, parietal cortex; PFA, perifornical area; PG, pontine gray; PPit, posterior pituitary; PPTg, pedunculopontine tegmental nucleus; R, red nucleus; RN, raphe nuclei; SC, superior colliculi; SN, substantia nigra; SON, supraoptic nucleus; SP5n, spinal trigeminal nucleus; SPO, superior paraolivary nucleus; Thal, thalamus.

the increase in emotionality (anxiety) is evoked by CRF-mediated CRF<sub>1</sub> activation and Ucn- or Ucn-III-mediated CRF<sub>2</sub> activation, presumably in the amygdala, BNST and/or iLS. However, as part of the recovery phase CRF<sub>2</sub>, following activation by Ucn, Ucn II and/or Ucn III, participates in reducing emotionality some hours after the stressful experience. Thus, CRF<sub>2</sub> has a dual mode of action on anxiety-related behavior. A challenge for the future will be to resolve the exact neural circuitry involved, the underlying molecular and cellular mechanisms, and the manner in which this dual action program is tuned by afferent neural input (e.g. from the frontal cortex, hippocampus, hypothalamus and autonomic centres) and humoral input (e.g. glucocorticoid hormones).

**HPA axis regulation**

Disturbances in HPA axis regulation seem to play a profound role in the etiology of major depression [52\*,53]. Moreover, studies on depressed patients have suggested that there is a close correlation between a stable remission of the clinical symptoms and a normalization of HPA regulation [54]. The cause for the aberrant — in most cases, hyperactive — HPA axis is thought to be a hyperactive central CRF system (for review, see [25,26,55–57]) and defunct brain and pituitary corticosteroid receptor systems [52\*,58,59\*]. More than a decade ago, a reduced CRF receptor density was found in the frontal cortex of depressed patients that had committed suicide [3]. Only recently have efforts been made to delineate CRF<sub>1</sub> and CRF<sub>2</sub> expression in post-mortem brains of depressed patients. In a recent study, investigators observed in pituitaries of suicide victims a shift in the ratio between CRF<sub>1</sub> (less) and CRF<sub>2</sub> (more) mRNA levels from normal levels, but it was unclear whether the victims had a history of major depressive illness [60]. Investigations into the role of CRF<sub>1</sub> and CRF<sub>2</sub> in HPA regulation have been mainly performed in rodents.

**CRF receptors**

Recent studies on CRF<sub>1</sub>- and CRF<sub>2</sub>-deficient mice indicate that these receptors play different roles in the HPA axis. CRF<sub>1</sub>-deficient mice are unable to mount a stress-induced HPA response in terms of circulating ACTH and corticosterone, but their baseline ACTH levels


are normal and baseline corticosterone levels virtually undetectable [28,29,61,62]. Thus, CRF<sub>1</sub> is crucial for stress-induced HPA responsiveness but not for the baseline hypothalamic-pituitary drive. In the PVH, only low levels of CRF<sub>1</sub> mRNA can be found but the levels of CRF<sub>1</sub> mRNA increase in response to stress [20\*,63–66] or i.c.v. administration of CRF [67]. This induction of CRF<sub>1</sub> mRNA may be implemented in the positive feedback action of CRF on PVH neurons, but this needs to be further explored.

Exposure of the CRF<sub>2</sub>-deficient and wild-type mice to restraint stress revealed changes in HPA axis regulation at different levels in two of the three mutant lines [46\*–48\*]. Kishimoto *et al.* [48\*] observed no changes, presumably because they analysed HPA activity at a single time-point. The other two CRF<sub>2</sub>-mutant mouse lines showed augmented responses in plasma ACTH and corticosterone levels to restraint stress [46\*,47\*]. The plasma ACTH levels in the mutant mice, however, decreased within 10 min of stress onset, earlier than in wild-type animals. Ten minutes after stress onset, the corticosterone levels continued to rise in the mutant mice, reaching higher levels than in the wild-type mice [46\*,47\*]. At 90 min after stress, corticosterone levels were still higher in the mutant mice than the wild-type mice. It is clear from these data that there is an array of changes in the HPA axis of CRF<sub>2</sub>-mutant mice that could explain the different hormonal responses. First, hypersensitivity of the corticotrophic cells to hypothalamic secretagogues; second, the higher glucocorticoid levels cause ACTH levels to come down earlier, via higher negative feedback inhibition; and third, the adrenal cortex of the mutant mice may be hypersensitive to ACTH [46\*,47\*]. Overall, these changes in HPA responses to stress suggest that CRF<sub>1</sub> and CRF<sub>2</sub> receptors act in an antagonistic manner: such that CRF<sub>1</sub> activates and CRF<sub>2</sub> attenuates the stress response. The sites of these antagonistic actions are presently not known, but might include the pituitary gland, the PVH, brain areas providing afferent input to the PVH such as the amygdala, BNST and the LS, and the sympathetic motor nuclei driving the sympatho-adrenomedullary pathway. Studies on the HPA axis of recently created mutant mice lacking both CRF<sub>1</sub> and CRF<sub>2</sub> receptors confirm the data obtained with the single gene mutants, although the CRF<sub>1</sub> receptor mutation has a

**Figure 2**

Effect of forced swim stress on rat hippocampal MR levels and its consequences for MR-mediated HPA axis regulation.

**(a)** Forced swimming induces, within 24 hours, an increase in MR-immunoreactivity in nuclei of pyramidal and granular neurons in the CA1, CA2, CA3 (not shown) hippocampal pyramidal layers and the dentate gyrus (DG). This effect was stressor-specific, as it was also seen after novelty stress, but not after exposure to a cold environment (not shown). **(b)** I.c.v. pretreatment with the non-selective CRF receptor antagonist (D-Phe<sup>12</sup>,Nle<sup>21,38</sup>, $\alpha$ -Me-Leu<sup>37</sup>)-CRF<sub>12-41</sub> (D-Phe-CRF<sub>12-41</sub>) prevented the forced-swimming-induced increase in hippocampal MRs. Moreover, i.c.v. CRF treatment mimics the effect of stress on hippocampal MR levels (not shown). **(c)** As shown in a RU 28318 challenge test, the forced-swimming-induced elevation in hippocampal MR levels is associated with a potentiated MR-mediated inhibition of HPA activity. RU 28318 is a selective MR antagonist and, after i.c.v. administration, releases the HPA axis from the tonic inhibitory control elicited by hippocampal MRs. The experiment was based on the idea that, when MRs are upregulated after stress, the release of HPA activity by RU 28318 would be exaggerated compared with the control, unstressed, situation. Thus, rats were stressed by forced swimming, injected i.c.v. with RU 28318 24 hours later and trunk blood was collected 30 min after injection. Indeed, the results show that the release of HPA activity in terms of plasma corticosterone levels was larger when rats had been stressed 24 hours earlier, indicating that the stress-induced



dominating influence, presumably because of its 'key' position on the anterior pituitary corticotrophic cells [68].

#### Corticosteroid receptors

In addition to the CRF receptors, corticosteroid receptors are also key elements in the regulation of the HPA axis [58,59]. They can be grouped into two types of corticosteroid-binding receptors: the mineralocorticoid receptor (MR or type I) and the glucocorticoid receptor (GR or type II) [69]. MRs are mainly localized in the hippocampus, whereas GRs have a widespread distribution in the central nervous system. They have different functions in HPA regulation, with MRs mediating the tonic inhibitory influence of the hippocampus (via the BNST) on parvocellular PVH neurons, and GRs mediating the negative feedback action of glucocorticoids on HPA activity [58,59,69]. Recently, we discovered a new mechanism of cross-talk between the CRF neuropeptide systems and the hippocampal MRs. It was found that acute stressors act via a CRF receptor mediated action to cause, within eight hours after stress, an elevation in MR levels in the hippocampus, which was associated with an augmented MR-mediated inhibition of HPA activity (Figure 2; [70\*\*]). Thus, CRF receptors are involved

in strengthening an important control instrument (the MR) of the HPA axis. Although the effect of stress could be mimicked by an i.c.v. injection of CRF, pointing to an involvement of CRF [70\*\*], exactly which CRF receptor mediates this phenomenon and where it is localized needs to be clarified. Furthermore, we have postulated that, given the eminent role of the CRF-MR pathway in maintaining control of HPA axis activity, in patients suffering from a stress-related disorder such as major depression, HPA hyperactivity might have developed as a result of MR induction becoming desensitized to CRF or CRF-like neuropeptides [59,70\*\*].

Summarizing, CRF<sub>1</sub> plays a critical role in the acute phase of the stress-induced HPA response, whereas CRF<sub>2</sub> is involved in the recovery phase. The stress-evoked increase in hippocampal MR expression appears to be part of the recovery phase but whether this element is mediated by CRF<sub>1</sub> or CRF<sub>2</sub> receptors needs clarification.


#### Significance for anxiety disorders and depression

An increased central CRF drive seems to be a feature often seen in major depression and anxiety disorders. This



Figure 2

Effect of forced swim stress on rat hippocampal MR levels and its consequences for MR-mediated HPA axis regulation. (a) Forced swimming induces, within 24 hours, an increase in MR-immunoreactivity in nuclei of pyramidal and granular neurons in the CA1, CA2, CA3 (not shown) hippocampal pyramidal layers and the dentate gyrus (DG). This effect was stressor-specific, as it was also seen after novelty stress, but not after exposure to a cold environment (not shown). (b) I.c.v. pretreatment with the non-selective CRF receptor antagonist (D-Phe<sup>12</sup>,Nle<sup>21,38</sup>, $\alpha$ -Me-Leu<sup>37</sup>)-CRF<sub>12-41</sub> (D-Phe-CRF<sub>12-41</sub>) prevented the forced-swimming-induced increase in hippocampal MRs. Moreover, i.c.v. CRF treatment mimics the effect of stress on hippocampal MR levels (not shown). (c) As shown in a RU 28318 challenge test, the forced-swimming-induced elevation in hippocampal MR levels is associated with a potentiated MR-mediated inhibition of HPA activity. RU 28318 is a selective MR antagonist and, after i.c.v. administration, releases the HPA axis from the tonic inhibitory control elicited by hippocampal MRs. The experiment was based on the idea that, when MRs are upregulated after stress, the release of HPA activity by RU 28318 would be exaggerated compared with the control, unstressed, situation. Thus, rats were stressed by forced swimming, injected i.c.v. with RU 28318 24 hours later and trunk blood was collected 30 min after injection. Indeed, the results show that the release of HPA activity in terms of plasma corticosterone levels was larger when rats had been stressed 24 hours earlier, indicating that the stress-induced



increase in hippocampal MR levels is associated with an enhanced MR-mediated tonic inhibitory control of HPA axis activity.

For further details, see [70\*\*]. Reprinted, with permission, from [70\*\*]; copyright 2001 by the Society for Neuroscience.

dominating influence, presumably because of its 'key' position on the anterior pituitary corticotrophic cells [68].

Corticosteroid receptors

In addition to the CRF receptors, corticosteroid receptors are also key elements in the regulation of the HPA axis [58,59\*]. They can be grouped into two types of corticosteroid-binding receptors: the mineralocorticoid receptor (MR or type I) and the glucocorticoid receptor (GR or type II) [69]. MRs are mainly localized in the hippocampus, whereas GRs have a widespread distribution in the central nervous system. They have different functions in HPA regulation, with MRs mediating the tonic inhibitory influence of the hippocampus (via the BNST) on parvocellular PVH neurons, and GRs mediating the negative feedback action of glucocorticoids on HPA activity [58,59\*,69]. Recently, we discovered a new mechanism of cross-talk between the CRF neuropeptide systems and the hippocampal MRs. It was found that acute stressors act via a CRF receptor mediated action to cause, within eight hours after stress, an elevation in MR levels in the hippocampus, which was associated with an augmented MR-mediated inhibition of HPA activity (Figure 2; [70\*\*]). Thus, CRF receptors are involved

in strengthening an important control instrument (the MR) of the HPA axis. Although the effect of stress could be mimicked by an i.c.v. injection of CRF, pointing to an involvement of CRF [70\*\*], exactly which CRF receptor mediates this phenomenon and where it is localized needs to be clarified. Furthermore, we have postulated that, given the eminent role of the CRF-MR pathway in maintaining control of HPA axis activity, in patients suffering from a stress-related disorder such as major depression, HPA hyperactivity might have developed as a result of MR induction becoming desensitized to CRF or CRF-like neuropeptides [59\*,70\*\*].

Summarizing, CRF<sub>1</sub> plays a critical role in the acute phase of the stress-induced HPA response, whereas CRF<sub>2</sub> is involved in the recovery phase. The stress-evoked increase in hippocampal MR expression appears to be part of the recovery phase but whether this element is mediated by CRF<sub>1</sub> or CRF<sub>2</sub> receptors needs clarification.

Significance for anxiety disorders and depression


An increased central CRF drive seems to be a feature often seen in major depression and anxiety disorders. This

Figure 3

Working hypothesis of limbic–HPA-axis interactions in anxiety and depressive disorders. On the basis of the presently established afferent and efferent regulatory interactions between the HPA axis and its limbic 'partners' (the hippocampus and the amygdala), we propose a framework giving a neuropharmacological basis to the psychiatric, neurovegetative and physiological disturbances seen in anxiety and depressive disorders. Patients suffering from major depression or pathological anxiety often show a dysregulated – mostly hyperactive – HPA axis, which is associated with increased CSF levels of CRF [26,55,56]. Apart from intrinsic HPA axis disturbances at the hypothalamic, pituitary or adrenal level, the reason for the HPA hyperactivity may well derive from defunct processes in the hippocampus and central nucleus of the amygdala (CeA) known to provide direct and indirect efferent projections to the PVH [59,81]. As postulated (see text), chronic stressful life events result in a loss of capacity of CRF or CRF-related peptides to upregulate hippocampal MR levels, (a) leading to a loosening of the tonic inhibitory influence on parvocellular neurons in the PVH [59]. In depressed patients and in a variety of animal models, a reduced expression of MR has indeed been found [58,59,82].

(b) Consequently, levels of CRF and co-expressed vasopressin will increase in these neurons (for review, see [52,57,59]), providing an enhanced drive on HPA activity, CRF<sub>1</sub> receptor desensitization in the anterior pituitary (APit) and adrenal hyperplasia [52,59].

(c) Subsequently, the elevated circulating glucocorticoid levels will raise CRF expression in the CeA [72], (d) resulting in an enhanced stimulatory influence on the PVH. In this manner, a positive feed-forward loop develops, accelerating the establishment of a state of sustained HPA hyperactivity. Importantly, regarding the activity of the efferent amygdaloid and hippocampal projections to the nucleus accumbens (NAcc), (e) a shift may occur toward an augmented input from the CeA relative to that from the hippocampus. Such a shift will result in an increased emotionality that is likely to develop in subjects genetically vulnerable to pathological anxiety and mood disorders. Finally, the enhanced caudally directed CeA activity leading to an increased sympathetic outflow in combination with the excess glucocorticoid levels can result in a variety of neurovegetative (e.g. cardiovascular and gastrointestinal problems), metabolic and



immune disturbances, often seen in anxiety, mood and psychosomatic disorders. Also, CeA-associated structures such as the cortical (CoA), basolateral (BLA) and medial (MA) amygdala, and hippocampus-associated structures such as the LS and medial septum (MS) are shown in the diagram (gray boxes) because they participate strongly in CeA and hippocampus functioning. In addition, their own function is modulated by incoming signals via CRF<sub>1</sub> and/or CRF<sub>2</sub> receptors. The BNST, containing both CRF<sub>1</sub> and CRF<sub>2</sub> receptors, is shown because it is an important relay station for hippocampal output to the PVH. Thus, this model can be used as a framework to investigate integratively the anxiogenic, anxiolytic, HPA-driving, HPA-restraining and other actions of CRH, Ucn, Ucn II and Ucn III. Such studies should also implement interactions of these neuropeptides with the classical neurotransmitters which, for the sake

of clarity, were not depicted in the scheme. Other structures that may participate were also excluded; for instance, thalamic paraventricular nucleus, which contains low to moderate CRF<sub>1</sub> levels [20,83]. Elucidating the interactions between the various components of this network will bring forward new pharmacotherapeutic strategies for the treatment of anxiety and depressive disorders. Yellow boxes show primary elements (brain regions and parts of the HPA axis) of the interactions between the limbic system and HPA axis. The different categories of pathological disturbances resulting from aberrant functioning of certain elements of the network are shown in pink ovals. The localization of CRF<sub>1</sub> is indicated in red and CRF<sub>2</sub> in blue; other important components, such as CRF, ACTH, glucocorticoids, and MR, are indicated in green. CRF<sub>11</sub>, CRF<sub>1</sub> mRNA expression that is inducible by stress or CRF.

notion stems from measurements of CRF levels in cerebrospinal fluid (CSF), CRF binding and CRF challenge tests [4,71]. Comparing a variety of studies revealed that elevated CRF in the CSF was not an equivocal finding in all studies but seemed to depend on certain factors associated with the depressive illness. In particular, those patients showing melancholia, psychosis, hypercortisolemia and

dexamethasone non-suppression had elevated CSF CRF levels (for review, see [55,56]). It is presently still unclear from where in the brain the elevated levels of CRF are produced. It is, however, unlikely that they are derived exclusively from the PVH. The hypersecreted CRF may originate from the central nucleus of the amygdala, where it is known that synthesis of the neuropeptide is under



positive control of glucocorticoid hormones [72]. Thus, those depressed patients who hypersecrete glucocorticoids — at least in part as a result of defunct hippocampal inhibition of HPA activity (see previous section and Figure 3) — would also in turn increase their CRF synthesis in the central amygdaloid nucleus. Indeed, hypercortisolemia in depressed patients is associated with elevated CSF CRF levels. The increased expression of CRF in the central amygdaloid nucleus might be responsible for the increases in emotionality and anxiety, and the neurovegetative instability often associated with major depression [73,74]. Moreover, the central amygdaloid nucleus exerts, via its direct and indirect (via the BNST) connections to the PVH, a stimulatory influence on the HPA axis [59\*]. We can speculate that in depressed patients a positive feed-forward loop might have established between the amygdala and the HPA axis. Given that the neural and humoral components of this loop have uncountable interactions with other — central and peripheral — systems, the consequences would be manifold, including effects on mood, cognition, libido, the cardiovascular system, immune system and metabolism (see Figure 3).

We postulated earlier that CRF<sub>1</sub> and CRF<sub>2</sub> receptors play different roles in stress-evoked anxiety, in which both receptors operate in different regions of the brain (e.g. central amygdaloid nucleus, BNST, iLS), in the acute (anxiogenic) phase of the stress response, and CRF<sub>2</sub> promotes anxiolysis during the stress recovery phase (see earlier section discussing the role of CRF<sub>2</sub> in anxiety and emotion). Also, we have described a parallel mechanism for the role of these receptors in the stress-induced HPA response. There are strong indications for a CRF-evoked CRF<sub>1</sub>-mediated hypersignaling in the brain of patients suffering from anxiety and depressive disorders. This condition is thought to be responsible for the increases in emotionality, HPA activity and neurovegetative disturbances seen in these patients. Indeed, a first exploratory clinical study in our clinical department at the Max Planck Institute of Psychiatry (Munich, Germany) in which depressed patients were treated with the non-peptidergic CRF<sub>1</sub> receptor antagonist R1219191, showed that blocking CRF<sub>1</sub> signaling in these patients resulted in a substantial reduction in the depression and anxiety scores [75\*\*]. The current status of research promises that CRF<sub>1</sub> receptor antagonists represent a novel pharmacotherapeutic strategy to treat depression, pathological anxiety (such as phobias and panic) and post-traumatic stress disorder. This recent development in the pharmacotherapy of mood and anxiety disorders is an important step toward the establishment of therapies based on scientific causality. It is more than likely that this development is also a significant step on the way to the ultimate goal of a pharmacotherapy with rapid onset of clinical effect, negligible side effects and no treatment resistance

It is still possible that, in addition to CRF<sub>1</sub> hyperfunction, CRF<sub>2</sub> receptor hypofunction might exist in depressed patients. Due to an impaired CRF<sub>2</sub>-mediated anxiolysis,

the subject might remain in an extended state of anxiety and arousal. Other stress recovery processes may also be impaired by the reduced CRF<sub>2</sub> activity, including HPA regulation and autonomic processes [15\*\*,46\*–48\*,76,77].

Figure 3 presents a working hypothesis based on an integration of the previously described issues. Our hypothetical model proposes that the development of anxiety and mood disorders is caused by a shift in the balance between the effects of the hippocampus and the central nucleus of the amygdala initially on the HPA axis, but eventually also on the nucleus accumbens and frontal cortex, which are brain regions involved in the regulation of affective states. The altered state of amygdaloid output is also expected to affect autonomic outflow which, in combination with the enhanced glucocorticoid secretion, could be responsible for the physiological, metabolic and immune disturbances often seen in depressed and anxious patients. The CRF neuropeptide family and its receptors are major participants in this network and with the recent growth of this family (i.e. Ucn II and Ucn III) a major step was made toward the elucidation of the roles of the CRF<sub>1</sub> and CRF<sub>2</sub> receptors in anxiety and depression.

Conclusions and perspectives

Overall, the blueprint of an intricate network controlling the acute and the recovery phase of the stress coping response is being drawn up. Recent advances — for example, the identification of new members of the CRF neuropeptide family, elucidating the dual function of CRF<sub>1</sub> and CRF<sub>2</sub> receptors in anxiety and HPA regulation and the CRF–MR regulatory shunt in HPA axis control — have provided the cornerstones enabling a significant leap in our understanding of the wiring and timing of the stress coping response. Of utmost importance is the acquired knowledge about the stress defense mechanisms underpinning anxiolysis, HPA control and autonomic stability.

These advances open the way for the development of novel classes of antidepressant drugs not just targeting the acute response systems but also acting supportively with regard to the stress defense mechanisms. To address this goal substantial investments are required to further elucidate the regulatory pathways and players governing the network in health and disease. With the recent development in the fields of functional genomics and pharmacogenomics (for instance, see [78\*\*]) and proteomics, built on the experience of several decades of research in stress physiology, neuroanatomy, pharmacology and molecular biology, this ambitious plan can be mastered.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
  - of outstanding interest
1. Vale W, Spiess J, Rivier C, Rivier J: **Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.** *Science* 1981, **213**:1394-1397.

2. Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: **Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.** *Science* 1984, **226**:1342-1344.
  3. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M: **Reduced corticotropin-releasing factor binding sites in the frontal cortex of suicide victims.** *Arch Gen Psychiatry* 1988, **45**:577-579.
  4. Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Müller OA: **Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression.** *New Eng J Med* 1984, **311**:1127.
  5. Holsboer F, Von Bardeleben U, Wiedemann K, Müller OA, Stalla GK: **Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression implications for pathophysiology of DST nonsuppression.** *Biol Psychiatry* 1987, **22**:228-234.
  6. Linthorst ACE, Flachskamm C, Hopkins SJ, Hoadley ME, Labeur MS, Holsboer F, Reul JMHM: **Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge.** *J Neurosci* 1997, **17**:4448-4460.
  7. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C *et al.*: **Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.** *Nature* 1995, **378**:287-292.
  8. Lederis K, Vale WW, Rivier JE, MacCannell KL, McMaster D, Kobayashi Y, Suess U, Lawrence J: **Urotensin I – a novel CRF-like peptide in catostomus commersoni urophysis.** *Proc West Pharmacol Soc* 1982, **25**:223-227.
  9. Montecucchi PC, Anastasi A, de Castiglione R, Erspamer V: **Isolation and amino acid composition of sauvagine. An active polypeptide from methanol extracts of the skin of the south american frog phyllomedusa.** *Int J Peptide Protein Res* 1980, **16**:191-199.
  10. Chen R, Lewis KA, Perrin MH, Vale WW: **Expression cloning of a human corticotropin-releasing-factor receptor.** *Proc Natl Acad Sci USA* 1993, **90**:8967-8971.
  11. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, Desouza EB, Oltersdorf T: **Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain.** *Proc Natl Acad Sci USA* 1995, **92**:836-840.
  12. Chalmers DT, Lovenberg TW, De Souza EB: **Localization of novel corticotropin-releasing factor receptor (CRF<sub>2</sub>) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF<sub>1</sub> receptor mRNA expression.** *J Neurosci* 1995, **15**:6340-6350.
  13. Lovenberg TW, Chalmers DT, Liu CG, Desouza EB: **CRF<sub>2α</sub> and CRF<sub>2β</sub> receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues.** *Endocrinology* 1995, **136**:4139-4142.
  14. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Sawchenko PE: **Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.** *Proc Natl Acad Sci USA* 2001, **98**:2843-2848.
- This study describes the cloning and initial characterization of a novel murine CRF-related peptide, Ucn II, which is a selective endogenous agonist of CRF<sub>2</sub>. Ucn II is expressed in the PVH, arcuate nucleus, supraoptic nucleus, locus coeruleus and brain-stem motor nuclei. On the basis of sequence homology, the authors propose to rename hURP to hUcn II. When mUcn II is administered i.c.v. into mice, it has a delayed behavioral effect to attenuate night-time feeding, has no effect on locomotion but, according to Valdez *et al.* [51\*\*], Ucn II has anxiolytic effects.
15. Hsu SY, Hsueh AJW: **Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor.** *Nat Med* 2001, **7**:605-611.
- A description of the cloning of human stresscopin and stresscopin-related peptide, which are identical to hUcn III [16\*\*] and hUcn II [14\*\*], respectively. As found for the urocortins, the stresscopins are specific CRF<sub>2</sub> receptor agonists. The peptides are expressed in brain as well as peripheral tissues. Intraperitoneal treatment of mice with the peptides reduced food intake, delayed gastric emptying and decreased heat-induced edema. The authors conclude that the stresscopins play a major role in stress-coping or 'countershock' responses.
16. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W *et al.*: **Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.** *Proc Natl Acad Sci USA* 2001, **98**:7570-7575.
- This paper describes the cloning of hUcn III and mUcn III, which are selective agonists of CRF<sub>2</sub> receptors. Ucn III has a restricted expression in brain and periphery (small intestine and skin). In the brain, it is found in the median preoptic nucleus, the anterodorsal part of the medial amygdala and in a cluster of neurons that stretches from the posterior part of the BNST, anterior and lateral hypothalamic areas, and a region lateral to the PVH, caudally extending to the rostral part of the dorsomedial hypothalamic nucleus (the perifornical area). Unfortunately, no functional characterization was done, but i.c.v. administered Ucn III seems to be anxiolytic in the plus-maze test (EP Zorrilla, personal communication).
17. Seasholtz AF, Burrows HL, Karolyi IJ, Camper SA: **Mouse models of altered CRH-binding protein expression.** *Peptides* 2001, **22**:743-751.
  18. Bittencourt JC, Vaughan J, Arias C, Rissman RA, Vale WW, Sawchenko PE: **Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors.** *J Comp Neurol* 1999, **415**:285-312.
  19. Bittencourt JC, Sawchenko PE: **Do centrally administered neuropeptides access cognate receptors? An analysis in the central corticotropin-releasing factor system.** *J Neurosci* 2000, **20**:1142-1156.
- These authors compared the CRF- and Ucn-induced Fos expression pattern in rat brain in relation to the localization of CRF<sub>1</sub> and CRF<sub>2</sub> mRNA. The CRF-induced Fos pattern matched the distribution of CRF<sub>1</sub> receptor mRNA, whereas the Ucn-induced activation pattern lined up with both CRF<sub>1</sub> and CRF<sub>2</sub> receptor mRNA, which is in accordance with its high binding affinity for both receptors. Nevertheless, some nuclei (e.g. central amygdaloid nucleus and the locus coeruleus) show Fos expression after CRF or Ucn application even though they express neither receptor type. This raises the question whether Fos expression in these nuclei is induced by trans-synaptic or other processes.
20. Van Pett K, Viau V, Bittencourt JC, Chan RKW, Li H-Y, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE: **Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.** *J Comp Neurol* 2000, **428**:191-212.
- This is an extremely comprehensive study presenting the distribution of CRF<sub>1</sub> and CRF<sub>2</sub> receptor mRNA in mouse and rat brain and pituitary.
21. Swanson LW, Sawchenko PE: **Hypothalamic integration: organization of the paraventricular and supraoptic nuclei.** *Ann Rev Neurosci* 1983, **6**:269-324.
  22. Bremner JD, Krystal JH, Southwick SM, Charney DS: **Noradrenergic mechanisms in stress and anxiety: I. preclinical studies.** *Synapse* 1996, **23**:28-38.
  23. Elmquist JK, Maratos-Flier E, Saper CB, Flier JS: **Unraveling the central nervous system pathways underlying responses to leptin.** *Nat Neurosci* 1998, **1**:445-450.
  24. Swanson LW, Sawchenko PE, Rivier J, Vale WW: **Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study.** *Neuroendocrinol* 1983, **36**:165-186.
  25. Owens MJ, Nemeroff CB: **Physiology and pharmacology of corticotropin-releasing factor.** *Pharmacol Rev* 1991, **43**:425-473.
  26. Holsboer F: **The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.** *J Psychiatr Res* 1999, **33**:181-214.
  27. Steckler T, Holsboer F: **Corticotropin-releasing hormone receptor subtypes and emotion.** *Biol Psychiatry* 1999, **46**:1480-1508.
  28. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JMHM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W: **Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1.** *Nat Genet* 1998, **19**:162-166.
  29. Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA *et al.*: **Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.** *Neuron* 1998, **20**:1093-1102.
  30. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW: **Overproduction of corticotropin-releasing factor in transgenic**

- mice: a genetic model of anxiogenic behavior. *J Neurosci* 1994, 14:2579-2584.
31. Heinrichs SC, Lapansky J, Lovenberg TW, De Souza EB, Chalmers DT: **Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior.** *Regul Pept* 1997, 71:15-21.
32. Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A: **Chronic infusion of a CRH<sub>1</sub> receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats.** *Regul Pept* 1995, 59:229-239.
33. Liebsch G, Landgraf R, Engelmann M, Lörcher P, Holsboer F: **Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain.** *J Psychiatr Res* 1999, 33:153-163.
34. Skutella T, Probst JC, Renner U, Holsboer F, Behl C: **Corticotropin-releasing hormone receptor (type 1) antisense targeting reduces anxiety.** *Neuroscience* 1998, 85:795-805.
35. Smagin GN, Dunn AJ: **The role of CRF receptor subtypes in stress-induced behavioural responses.** *Eur J Pharmacol* 2000, 405:199-206.
36. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, Tomisawa K: **Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA 1000 and CRA 1001.** *J Pharmacol Exp Ther* 1999, 289:926-935.
37. Holsboer F: **CRHR1 Antagonists as novel treatment strategies.** *CNS Spectrums* 2001, 6:590-594.
38. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE: **Brain penetration, receptor occupancy and anti-stress in vivo efficacy of a small molecule corticotropin-releasing factor<sub>1</sub> receptor selective antagonist.** Abstract 8078 of the 30th Annual Meeting of the Society for Neuroscience, 2000 November 4-9, New Orleans.
39. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW: **The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.** *Endocrinology* 1999, 140:79-86.
40. Fiorino DF, Kagaya T, Shibata H, Nishizawa Y: **The CRF receptor 1 antagonist, antalarmin, decreases anxiety as assessed by the shock-probe burying test in rats.** Abstract 851.3 of the 30th Annual Meeting of the Society for Neuroscience, 2000 November 4-9, New Orleans.
41. Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzgerald LW, McElroy J, Smith MA, Shen HSL, Saye JA *et al.*: **The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo[1,5- $\alpha$ ]-pyrimidine: a corticotropin-releasing factor (hCRF<sub>1</sub>) antagonist.** *Bioorg Med Chem* 2000, 8:181-189.
42. Gilligan PJ, Robertson DW, Zaczek R: **Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.** *J Med Chem* 2000, 43:1641-1660.
43. He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, Saye JA, Kalin NH, Shelton S, Christ D *et al.*: **4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5- $\alpha$ ]-1,3,5-triazine: a potent, orally bioavailable CRF<sub>1</sub> receptor antagonist.** *J Med Chem* 2000, 43:449-456.
44. Tian X, Hsin L-W, Webster E, Contoreggi C, Chrousos GP, Gold PW, Habib K, Ayala A, Eckelman WC, Jacobson AE, Rice KC: **The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type 1.** *Bioorg Med Chem Lett* 2001, 11:331-333.
45. Hsin L-W, Webster EL, Chrousos GP, Gold PW, Eckelman WC, Contoreggi C, Rice KC: **Synthesis and biological activity of fluoro-substituted Pyrrolo[2,3- $d$ ]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor.** *Bioorg Med Chem Lett* 2000, 10:707-710.
46. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR *et al.*: **Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2.** *Nat Genet* 2000, 24:403-409.
- This study describes the creation and characterization of CRF<sub>2</sub>-deleted mutant mice. The mice show complex changes in HPA regulation (both sexes), transient i.c.v. Ucn-induced suppression of feeding (both sexes) and elevated basal blood pressure (tested in females only). Male and female mice do not show differences in anxiety-like behavior in the elevated plus-maze test and, also, the small difference in behavior in an open field did not reach statistical significance. However, the CRF<sub>2</sub>-deleted male and female mice showed a strongly reduced grooming response in the open field, pointing to reduced coping and de-arousal capacity. The authors conclude that the CRF<sub>2</sub> receptor plays a role in the recovery phase of the stress coping response (e.g. attenuation of stress-induced HPA activity, de-arousal, hypotension and cardioprotection).
47. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee K-F: **Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.** *Nat Genet* 2000, 24:410-414.
- Independent of Coste *et al.* [46\*], Bale *et al.* [47\*] developed another CRF<sub>2</sub> receptor deleted mouse line. These mice show similar changes in the HPA axis as described in [46\*]. Baseline feeding and weight gain were normal, but a decrease in food intake was found 24 hours after food deprivation without causing a difference in body weight or refeeding, compared with the wild-type animals. The mutant mice presented increased anxiety-like behavior in the plus-maze and open-field tests, but not in the light-dark box. The CRF<sub>2</sub>-deleted mice did not show a hypotensive response to peripherally injected Ucn, which fits with the concept of the role of CRF<sub>2</sub> in blood pressure regulation and is in line with the data reported in [46\*]. No sex differences were observed.
48. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmaand F, Hermanson O, Rosenfeld MG, Spiess J: **Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2.** *Nat Genet* 2000, 24:415-419.
- This study concerns the creation and characterization of a third CRF<sub>2</sub>-deleted mouse line. The male, but not female, mutant mice showed increased anxiety in the elevated plus-maze, light-dark box and open-field tests. No changes were found in both male and female mice in stress-induced HPA responses, but this may be due to the single-time point assessment. Mutant mice (both sexes) showed increased thermal injury in terms of edema formation, which is consistent with the decreased thermal injury found in mice treated with Ucn II and Ucn III [15\*\*].
49. Crawley JN: **Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests.** *Brain Res* 1999, 835:18-26.
50. Radulovic J, Rühmann A, Liepold T, Spiess J: **Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2.** *J Neurosci* 1999, 19:5016-5025.
51. Valdez GR, Inoue K, Koob GF, Rivier J, Vale WW, Zorrilla EP: **Human urocortin II: effects of a novel, selective CRF-R2 receptor agonist on anxiety and motor activation in rats.** Abstract 320.13 of the 31st Annual Meeting of the Society for Neuroscience, 2001 November 10-15, San Diego.
- The study shows that i.c.v.-administered Ucn II in rats, reduces anxiety in a delayed manner in the elevated plus-maze test and has a mild suppressive effect on locomotor activity. Ucn III had a similar effect (EP Zorrilla, personal communication).
52. Holsboer F: **The corticosteroid receptor hypothesis of depression.** *Neuropsychopharmacol* 2000, 23:477-501.
- A comprehensive review on the role of brain and pituitary corticosteroid receptors in the etiology of depression.
53. Steckler T, Holsboer F, Reul JMHM: **Glucocorticoids and depression.** *Baillière's Clin Endocrinol Metab* 1999, 13:107-124.
54. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M: **Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study.** *J Psychiatr Res* 2001, 35:83-94.
55. Keck ME, Holsboer F: **Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders.** *Peptides* 2001, 22:835-844.
56. Kasckow JW, Baker D, Geraciotti TD Jr: **Corticotropin-releasing hormone in depression and post-traumatic stress disorder.** *Peptides* 2001, 22:845-851.
57. Swaab DF: **Hypothalamic peptides in human brain diseases.** *Trends Endocrinol Metab* 1999, 10:236-244.

58. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M: **Brain corticosteroid receptor balance in health and disease.** *Endocr Rev* 1998, 19:269-301.
  59. Reul JM, Gesing A, Droste S, Stec ISM, Weber A, Bachmann C, Bilang-Bleuel A, Holsboer F, Linthorst ACE: **The brain mineralocorticoid receptor: greedy for ligand, mysterious in function.** *Eur J Pharmacol* 2000, 405:235-249.
- A review specifically focusing on the brain mineralocorticoid receptor. Starting from a historical perspective, a detailed survey is presented about the somewhat unusual characteristics of this receptor. The review focuses on a newly described role for the MR in HPA regulation (see also [70\*\*]) and its implications for the HPA disturbances seen in depressive disorders.
60. Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW, Chrousos GP, Bornstein SR: **Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls.** *Mol Psychiatry* 2001, 6:540-546.
  61. Peñalva RG, Flachskamm C, Zimmermann S, Wurst W, Holsboer F, Reul JM, Linthorst ACE: **Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: an *in vivo* microdialysis study in mutant mice.** *Neuroscience* 2002, in press.
  62. Müller MB, Landgraf R, Preil J, Sillaber I, Kresse AE, Keck ME, Zimmermann S, Holsboer F, Wurst W: **Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids.** *Endocrinology* 2000, 141:4262-4269.
  63. Luo X, Kiss A, Makara G, Lolait SJ, Aguilera G: **Stress-specific regulation of corticotropin releasing hormone receptor expression in the paraventricular and supraoptic nuclei of the hypothalamus in the rat.** *J Neuroendocrinol* 1994, 6:689-696.
  64. Rivest S, Laflamme N, Nappi RE: **Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus.** *J Neurosci* 1995, 15:2680-2695.
  65. Makino S, Schulkin J, Smith MA, Pacak K, Palkovits M, Gold PW: **Regulation of corticotropin-releasing hormone receptor messenger ribonucleic acid in the rat brain and pituitary by glucocorticoids and stress.** *Endocrinology* 1995, 136:4517-4525.
  66. Imaki T, Katsumata H, Miyata M, Naruse M, Imaki J, Minami S: **Expression of corticotropin-releasing hormone type 1 receptor in paraventricular nucleus after acute stress.** *Neuroendocrinol* 2001, 73:293-301.
  67. Mansi JA, Rivest S, Drolet G: **Regulation of corticotropin-releasing factor type 1 (CRF1) receptor messenger ribonucleic acid in the paraventricular nucleus of rat hypothalamus by exogenous CRF.** *Endocrinology* 1996, 137:4619-4629.
  68. Preil J, Müller MB, Gesing A, Reul JM, Sillaber I, van Gaalen MM, Landgrebe J, Holsboer F, Stenzel-Poore M, Wurst W: **Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2.** *Endocrinology* 2001, 142:1-10.
  69. Reul JM, De Kloet ER: **Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.** *Endocrinology* 1985, 117:2505-2512.
  70. Gesing A, Bilang-Bleuel A, Droste SK, Linthorst ACE, Holsboer F, Reul JM: **Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone.** *J Neurosci* 2001, 21:4822-4829.
- This study describes that psychological stresses such as forced swimming and exposure to a novel environment upregulate MR levels in the hippocampus, an effect mediated by CRF receptors. This effect is accompanied by an enhanced MR-mediated tonic inhibition of HPA activity. Thus, the paper presents a novel mechanism showing the existence of a dynamic organization of HPA axis regulation involving a principal role for CRF receptors and MR.
71. Amsterdam JD, Maislin G, Winokur A, Kling M, Gold P: **Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers.** *Arch Gen Psychiatry* 1987, 44:775-781.
  72. Schulkin J, Gold PW, McEwen BS: **Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load.** *Psychoneuroendocrinol* 1998, 23:219-243.
  73. Davis M: **The role of the amygdala in conditioned fear.** In *The Amygdala*. Edited by Aggleton JP. New York: Wiley-Liss; 1992:255-306.
  74. Gray TS: **The organization and possible function of amygdaloid corticotropin-releasing factor pathways.** In *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide*. Edited by De Souza EB, Nemeroff CB. Boca Raton, Florida: CRC Press; 1990:53-68.
  75. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F: **Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.** *J Psychiatr Res* 2000, 34:171-181.
- The first exploratory study on the effects of the non-peptidergic selective CRF<sub>1</sub> receptor antagonist in depressed patients. The data show that the antagonist has significant anxiolytic and antidepressant effects.
76. Martínez V, Taché Y: **Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats.** *Brain Res* 2001, 893:29-35.
  77. Briscoe RJ, Cabrera CL, Baird TJ, Rice KC, Woods JH: **Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.** *Brain Res* 2000, 881:204-207.
  78. Gratacòs M, Nadal I, Martín-Santos R, Pujana MA, Gago J, Peral B, Armengol L, Ponsa I, Miró R, Bulbena A, Estivill X: **A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders.** *Cell* 2001, 106:367-379.
- This study demonstrates a susceptibility factor for anxiety disorders (such as panic and phobia and joint laxity) that is present in 7% of control subjects. It comprises an interstitial duplication of human chromosome 15q24-26 (called DUP25) which is transmitted in a non-Mendelian way. This discovery could have strong implications for research in this field of psychiatry and the treatment strategies of these disorders in the future.
79. Dautzenberg FM, Kilpatrick GJ, Hauger RL, Moreau J-L: **Molecular biology of the CRH receptors – in the mood.** *Peptides* 2001, 22:753-760.
  80. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K, Sawchenko PE, Vale W: **Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary.** *Proc Natl Acad Sci USA* 1994, 91:8777-8781.
  81. Bhatnagar S, Dallman M: **Neuroanatomical basis for facilitation of hypothalamic-pituitary-adrenal responses to a novel stressor after chronic stress.** *Neuroscience* 1998, 84:1025-1039.
  82. Lopez JF, Chalmers DT, Little KY, Watson SJ: **Regulation of serotonin<sub>1A</sub>, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus – implications for the neurobiology of depression.** *Biol Psychiatry* 1998, 43:547-573.
  83. Bhatnagar S, Viau V, Chu A, Soriano L, Meijer OC, Dallman MF: **A cholecystokinin-mediated pathway to the paraventricular thalamus is recruited in chronically stressed rats and regulates hypothalamic-pituitary-adrenal function.** *J Neurosci* 2000, 20:5564-5573.